약학회지 (YAKHAK HOEJI)

  • 제55권1호
  • /
  • Pages.11-15
  • /
  • 2011
  • /
  • 0377-9556(pISSN)
  • /
  • 2383-9457(eISSN)
대한약학회 (The Pharmaceutical Society of Korea)
권호 표지

그람양성세균에 대한 새로운 퀴놀론계 항균제 Zabofloxacin의 항균력

Antibacterial Activity of Zabofloxacin, a Novel Fluoroquinolone, against Gram-Positive Bacteria

  • 박희수 (한동대학교 생명과학부) ;
  • 정성지 (한동대학교 생명과학부) ;
  • 정지웅 (한동대학교 생명과학부) ;
  • 최동락 (동화약품 중앙연구소) ;
  • 김효현 (서울대학교 약학대학 종합약학연구소) ;
  • 최응칠 (서울대학교 약학대학 종합약학연구소) ;
  • 곽진환 (한동대학교 생명과학부)
  • Park, Hee-Soo (School of Life Science, Handong Global University) ;
  • Jung, Sung-Ji (School of Life Science, Handong Global University) ;
  • Jeong, Ji-Woong (School of Life Science, Handong Global University) ;
  • Choi, Dong-Rack (Dong Wha Pharmaceutical Industry Ltd.) ;
  • Kim, Hyo-Hyun (College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University) ;
  • Choi, Eung-Chil (College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University) ;
  • Kwak, Jin-Hwan (School of Life Science, Handong Global University)
  • 투고 : 2010.10.22
  • 심사 : 2010.11.16
  • 발행 : 2011.02.28
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Zabofloxacin is a novel broad spectrum fluoroquinolone with excellent anti-pneumococcal activity. We investigated the in vitro activity of zabofloxacin against clinical isolates of gram-positive bacteria and the in vivo activity against systemic infection in mice. Zabofloxacin was very active against gram-positive bacteria except QRSA (Quinolone-resistant S. aureus) and VRE(Vancomycin-resistant Enterococci). Especially, zabofloxacin was extremely potent against clinical isolates of Streptococci. Zabofloxacin was as active as gemifloxacin against systemic infection in mice. In view of its improved antibacterial activities against gram-positive bacteria and good pharmacokinetic profiles in animals, the clinical usefulness of zabofloxacin should be established by further studies.

키워드

참고문헌

  1. Hooper, D. C. and Rubinstein, E. : Quinolone antimicrobial agents. ASM Press. (2003).
  2. Emmerson, A. M. and Jones, A. M. : The quinolones: decades of development and use. J. Antimicrob. Chemother. 51(Suppl. S1), 13 (2003).
  3. Levy, S. B. and Marshall, B. : Antibacterial resistance worldwide: causes, challenges and responses. Nat. Med. 10, s122 (2004). https://doi.org/10.1038/nm1145
  4. Oh, J. I., Paek, K. S., An, M. J., Kim, M. Y., Hong, C. Y., Kim, I. C. and Kwak, J. H. : In vitro and in vivo evaluations of LB20304, a new Fluoronaphthyridone. Antimicrob. Agents Chemother. 40, 1564 (1996).
  5. Park, H. S., Kim, H. J., Seol, M. J., Choi, D. R., Choi, E. C. and Kwak, J. H. : In vitro and in vivo antibacterial activities of DW-224a, a new fluoronaphthyridone. Antimicrob. Agents Chemother. 50, 2261 (2006). https://doi.org/10.1128/AAC.01407-05
  6. Kim, H. J., Seol, M. J., Park, H. S., Choi, D. R., Seong, S. K., Shin, H. K. and Kwak, J. H. : Antimicrobial activity of DW- 224a, a new fluoroquinolone, against Streptococcus pneumoniae. J. Antimicrob. Chemotherapy 57, 1256 (2006). https://doi.org/10.1093/jac/dkl144
  7. Kwon, A. R., Min, Y. H., Ryu, J. M., Choi, D. R., Shim, M. J. and Choi, E. C. : In vitro and in vivo activities of DW-224a, a novel fluoroquinolone antibiotic agent. J. Antimicrob. Chemother. 58, 684 (2006). https://doi.org/10.1093/jac/dkl304
  8. Kosowska-Shick, K., Credito, K., Pankuch, G. A., Lin, G., Bozdogzn, B., McGhee, P., Dewasse, B., Choi, D. R., Ryu, J. M. and Appelbaum, P. C. : Antipneumococcal activity of DW-224a, a new quinolone, compared to those of eight other agents. Antimicrob. Agents Chemother. 50, 2064 (2006). https://doi.org/10.1128/AAC.00153-06
  9. Clinical and Laboratory Standards Institute (CLSI), Performance standards for antimicrobial susceptibility testing; 15th informational Supplement. Document M100-S15, CLSI, Wayne, PA (2005).
  10. Bliss, C. I. : Statistics in bioassay. Academic Press, Inc., New York (1985).
  11. Acar, J. F. and Francoual, S. : The clinical problems of bacterial resistance to the new quinolones. J. Antimicrob. Chemother. 26(Suppl B), 207 (1990). https://doi.org/10.1093/jac/26.suppl_B.207
  12. Hamett, N., Brown, S. and Krishnan, C. : Emergence of quinolone resistance among clinical isolate of methicillinresistant Staphylococcus aureus in Ontario, Canada. Antimicrob. Agents Chemother. 35, 1911 (1991). https://doi.org/10.1128/AAC.35.9.1911
  13. Domagala, J. M. : Structure-activity and structure-side effect relationships for the quinolone antibacterials. J. Antimicrob. Chemother. 33, 685 (1994). https://doi.org/10.1093/jac/33.4.685
  14. Hong, C. Y., Kim, Y. K., Lee, Y. H. and Kwak, J. H. : Methyloxime-substituted aminopyrrolidine: A new surrogate for 7-basic group of quinolone. Bioorganic & Medical Chemistry Letters. 8, 221 (1998). https://doi.org/10.1016/S0960-894X(97)10222-0
  15. Kim, E. J., Shin, W. H., Kim, K. S. and Han, S. S. : Safety pharmacology of DW-224a, a novel fluoroquinolone antibiotic agent. Drug Chem. Toxicol. 27, 295 (2004). https://doi.org/10.1081/DCT-200039708
  16. Han, J., Kim, J. C., Chung, M. K., Kim, B. and Choi, D. R. : Subacute toxicity and toxikinetics of a new antibiotics, DW- 224a, after single and 4-week repeated oral administration in dogs. Biol. Pharm. Bull. 26, 832 (2003). https://doi.org/10.1248/bpb.26.832
  17. Park, H. S., Jung, S. J., Choi, D. R., Choi, E. C. and Kwak, J. H. : DNA gyrase and topoisomerase IV are dual targets of zabofloxacin in Streptococcus pneumoniae. Int. J. Antimicrob. Agents. 36, 97 (2010). https://doi.org/10.1016/j.ijantimicag.2010.02.022